Rare frameshift mutation Cys475Tyrfs(*)11 in the BCR/ABL kinase domain contributes to imatinib mesylate resistance in 2 Korean patients with chronic myelogenous leukemia

Ann Lab Med. 2012 Nov;32(6):452-4. doi: 10.3343/alm.2012.32.6.452. Epub 2012 Oct 17.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Asian People / genetics*
  • Base Sequence
  • Benzamides / therapeutic use
  • Drug Resistance, Neoplasm
  • Female
  • Frameshift Mutation
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Republic of Korea
  • Sequence Analysis, DNA
  • Young Adult

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl